Capital Expanse RA Capital Management operates at scale with over 250 employees and more than $14 billion in assets under management, signaling a broad investor capacity and potential for larger co-investment rounds across public and private healthcare and life sciences opportunities.

Active Portfolio The firm is deeply engaged across multiple late-stage and growth ventures, including recent Series A to Series C rounds in companies such as cAMPfield Therapeutics, Slate Medicines, Contraline, Secretome Therapeutics, Stipple Bio, Terrestrial Bio, and Atavistik Bio, indicating a strong appetite for continued funding and strategic partnerships.

Healthcare Focus RA Capital’s emphasis on evidence-based, science-led investing in healthcare, life sciences, and planetary health suggests sales opportunities for diagnostic tools, platform technologies, biotech services, and contract research or development partnerships that align with their diligence-driven approach.

Strategic Ecosystem RA Capital’s Raven incubator and TechAtlas diligence framework imply potential collaboration for portfolio companies needing strategic advisory, scientific due diligence support, and access to a broad network of co-investors, potential acquirers, andLPs.

Technology Enablement Their tech stack includes Google Cloud, Tableau, Slack, Jira, Confluence and AI/ML capabilities (evidenced by cloud and analytics tooling), presenting opportunities to offer data infrastructure, analytics acceleration, cybersecurity, and knowledge-management solutions tailored to a data-driven investment firm.